Literature DB >> 10671777

Current status of minimally invasive treatment options for localized prostate carcinoma.

H P Beerlage1, S Thüroff, S Madersbacher, A R Zlotta, G Aus, T M de Reijke, J J de la Rosette.   

Abstract

INTRODUCTION: Prostate cancer is the leading malignancy in men today and an increase in detected localized prostate cancers is expected in the years to come. Even though radical prostatectomy is an effective treatment, it is associated with a considerable morbidity in some cases and efforts are made to provide minimally invasive alternative treatment options with equal efficacy but fewer side effects.
METHODS: Cryosurgical ablation of the prostate (CSAP), brachytherapy, high-intensity focused ultrasound (HIFU) and radiofrequency interstitial tumor ablation (RITA) were evaluated after a literature review from a Medline Search (1966-1998). Furthermore, personal experience and latest data from the authors were taken into account.
RESULTS: All alternative treatments nowadays make use of sophisticated technology, including the latest ultrasound devices for exact planning and monitoring of treatment, leading to increased safety compared to treatments in the 1960s and 1970s. Five-year results of CSAP show a PSA <1 ng/ml in 60% of cases whereas brachytherapy is able to achieve PSA <1 ng/ml in 80% of cases in a selected group. Recent outcome data come close to results of radical prostatectomy series. HIFU and RITA are promising new technologies that proved to be able to induce extensive necrosis, but the follow-up is too short to determine their definite places in the treatment of prostate cancer.
CONCLUSION: Two alternative treatment options for localized prostate carcinoma, CSAP and brachytherapy, have been studied with a sufficient number of patients and an adequate follow-up. The overall results of brachytherapy are favorable when compared to CSAP and are in the same range as the outcome after radical prostatectomy. HIFU and RITA are relatively new techniques based on sophisticated technology that are very promising at present, but a longer follow-up is mandatory.

Entities:  

Mesh:

Year:  2000        PMID: 10671777     DOI: 10.1159/000020091

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  9 in total

Review 1.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

2.  Referenceless MR thermometry for monitoring thermal ablation in the prostate.

Authors:  Viola Rieke; Adam M Kinsey; Anthony B Ross; William H Nau; Chris J Diederich; Graham Sommer; Kim Butts Pauly
Journal:  IEEE Trans Med Imaging       Date:  2007-06       Impact factor: 10.048

3.  In vivo guidance and assessment of liver radio-frequency ablation with acoustic radiation force elastography.

Authors:  Brian J Fahey; Rendon C Nelson; Stephen J Hsu; David P Bradway; Douglas M Dumont; Gregg E Trahey
Journal:  Ultrasound Med Biol       Date:  2008-05-09       Impact factor: 2.998

4.  Dynamic frame selection for in vivo ultrasound temperature estimation during radiofrequency ablation.

Authors:  Matthew J Daniels; Tomy Varghese
Journal:  Phys Med Biol       Date:  2010-07-30       Impact factor: 3.609

5.  3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study.

Authors:  Matthias P Lichy; Jörg Pintaske; Raimund Kottke; Jürgen Machann; Aristotelis Anastasiadis; Stefan Roell; Jörg Hennenlotter; Till Diergarten; Fritz Schick; Arnulf Stenzl; Claus D Claussen; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

6.  Growth inhibition of high-intensity focused ultrasound on hepatic cancer in vivo.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Yan-Rong Lu; Jie Zhang; Bo-Tao Liu; Wen-Fu Zeng; Yue-Ming He; Yu-Rui Fu
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

Review 7.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

Review 8.  Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.

Authors:  Afroz Abidi
Journal:  J Pharmacol Pharmacother       Date:  2013-10

9.  Double-parabolic-reflectors acoustic waveguides for high-power medical ultrasound.

Authors:  Kang Chen; Takasuke Irie; Takashi Iijima; Takeshi Morita
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.